Ann: CLTX CAR T PRESENTS POSITIVE INITIAL PHASE 1 CLINICAL DATA, page-57

They are all issues to be resolved.

Does CLTX CAR T cause cerebral edema?

If the dose is increased, do we expect a higher occurrence of cerebral edema?

Does CLTX CAR T at low dose cause disease stability?….We will know more in time.

Can CHM explain the mechanism of action to the FDA?

If CLTX CAR T improves patient outcomes then CHM doesn’t need to prove mechanisms of actions and a percentage of cerebral edema events or other adverse events may be overlooked for the benefit of other cohorts.

You and others appear to be very defensive. It’s a concern, imv.